title: [Foscarnet sodium for treatment in patients with severe chronic hepatitis B].
abstract: OBJECTIVE
  To investigate the effectiveness of foscarnet sodium in the treatment of severe chronic hepatitis B.
  
  
  METHODS
  Two hundred and eight patients were enrolled in a multicenter, double-blind, controlled study. The patients received foscarnet sodium (foscarnet group) or saline (control group) injections for 4 weeks, and were then followed for 24 weeks.
  
  
  RESULTS
  HBV DNA negative rate was 12.8% in the foscarnet group and 7.1% in the control group at the end of treatment; and it was 5.5% and 3.0% at the end of the follow-up period respectively (P > 0.05). The rate of HBV DNA decrease of more than 2 log copies/ml was 53.2% in the foscarnet group and 16.2% in the control group at the end of treatment, and 23.9% and 8.1% (P < 0.01) respectively at the end of the follow-up period. The rate of HBV DNA < 10(5) copies/ml was 64.2% and 30.3% at week 4 in the two groups respectively, and 40.4% and 22.2% (P < 0.01) at the end of the follow-up period. HBeAg negative rate was 17.3% and 5.8% at the end of the treatment, and 22% and 5.4% at the end of the follow-up period (P < 0.01). The rate of HBeAg seroconversion was 12.7% and 3.7% at week 4, and 16.7% and 1.5% at the end of the follow-up period. Response rate was 60.6% and 21.2% at the end of week 4 (P < 0.05).
  
  
  CONCLUSIONS
  Foscarnet sodium injection has a good effect on severe chronic hepatitis B patients and it is safe to use on them.
authors.affiliation: Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China.
authors.forename: Yan-yan
authors.initials: YY
authors.lastname: Yu
authors.forename: Da-zhi
authors.initials: DZ
authors.lastname: Zhang
authors.forename: Xiao-hui
authors.initials: XH
authors.lastname: Miao
authors.forename: Chuan-lin
authors.initials: CL
authors.lastname: Zhu
authors.forename: Xia-qiu
authors.initials: XQ
authors.lastname: Zhou
authors.forename: Hao
authors.initials: H
authors.lastname: Yu
authors.forename: Chong-wen
authors.initials: CW
authors.lastname: Si
mesh_terms: D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D017245:Foscarnet / Q000009:adverse effects / Q000627:therapeutic use*; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D017245:Foscarnet